Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to ...

Alastair Reeves has followed in his father's footsteps, using genetics to help farmers solve problems on farm by breeding ...

Heart disease in families is a warning, not a destiny. While genes play a role, lifestyle choices hold immense power. Knowing ...

Fintel reports that on October 29, 2025, Wedbush initiated coverage of Opus Genetics (NasdaqCM:IRD) with a Outperform ...

Genetic testing is transforming healthcare through personalized medicine, enabling early diagnosis, targeted treatments, and a future of more precise, patient-centered care.

Analysts estimate that Myriad Genetics will report an earnings per share (EPS) of $-0.05. The announcement from Myriad Genetics is eagerly anticipated, with investors seeking news of surpassing ...

The neurologic disease called chronic traumatic encephalopathy or CTE has most often been found in people who experienced ...

The consensus estimate for Q3 2025 revenue is $204.90 million, and the earnings are expected to come in at -$0.22 per share.

Prenatal testing revenue in the third quarter of 2025 grew 2% year-over-year, reflecting ongoing expansion of payer coverage, particularly for Foresight Expanded Carrier Screen. Prenatal volume over ...

A large biobanking effort captures genetic and health data from half a million people in Taiwan, widening the diversity of ...

Autism Spectrum Disorder is a complex condition with rising global prevalence. Research indicates it stems from a blend of ...

A new reptile genetics testing company, Phenome, is working on fully mapping out the genomes of a number of reptile species for the first time. The company first made its debut this year at the North ...